Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 Pathways for treatment of lung cancer and hnscc

Cancer Research

Volumn 75, Issue 20, 2015, Pages 4398-4406

  Singleton, Katherine R ^a   Hinz, Trista K ^a   Kleczko, Emily K ^a   Marek, A Lindsay ^a   Kwak, Jeff ^a   Harp, Taylor ^b   Kim, Jihye ^b   Tan, Aik Choon ^b   Heasley, Lynn E ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 4547; AZD 8055; CASPASE 3; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MAMMALIAN TARGET OF RAPAMYCIN; PONATINIB; PROTEIN TYROSINE KINASE; VISTUSERTIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; MORPHOLINE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DRUG PROTEIN BINDING; FUNCTIONAL GENOMICS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; ESSENTIAL GENE; GENE LIBRARY; GENETICS; GENOMICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE LIBRARY; GENES, ESSENTIAL; GENOMICS; HUMANS; LUNG NEOPLASMS; MORPHOLINES; PIPERAZINES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PYRAZOLES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945556079     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0509     Document Type: Article

References (29)

1. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small cell lung cancer cells. Mol Pharmacol 2009;75: 196-207
2. Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res 2014;20: 3299-309
3. Harding TC, Long L, Palencia S, Zhang H, Sadra A, Hestir K, et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med 2013;5:178ra39
4. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PloS ONE 2011;6:e20351
5. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62ra93
6. Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, et al. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res 2011;17:5016-25
7. Goke F, Bode M, Franzen A, Kirsten R, Goltz D, Goke A, et al. Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck. Modern Pathol 2013;26:1298-306
8. Marek LA, Hinz TK, von Massenhausen A, Olszewski KA, Kleczko EK, Boehm D, et al. Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma. Mol Cancer Res 2014;12:1460-9
9. Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-Amplified or mutated cancer models. Mol Cancer Therapeutic 2012;11:690-9
10. West H, Oxnard GR, Doebele RC. Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. Am Soc Clin Oncol Educ Book 2013. doi: 10.1200/EdBook- AM.2013.33.e272
11. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82
12. Glickman MS, Sawyers CL. Converting cancer therapies into cures: lessons from infectious diseases. Cell 2012;148:1089-98
13. Garraway LA, Janne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Dis 2012;2:214-26
14. Xu AM, Huang PH. Receptor tyrosine kinase coactivation networks in cancer. Cancer Res 2010;70:3857-60
15. Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012;72:2045-56
16. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant, and overcomes mutation-based resistance. Cancer Cell 2009;16:401-12
17. Kim J, Tan AC. BiNGS!SL-seq: a bioinformatics pipeline for the analysis and interpretation of deep sequencing genome-wide synthetic lethal screen. Methods Mol Biol 2012;802:389-98
18. Pike KG, Malagu K, Hummersone MG, Menear KA, Duggan HM, Gomez S, et al. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorganic Med Chem Lett 2013;23:1212-6
19. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6
20. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Therapeutic 2010;9:1956-67
21. Heerding DA, Rhodes N, Leber JD, Clark TJ, Keenan RM, Lafrance LV, et al. Identification of 4-(2-(4-Amino-1, 2, 5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4, 5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem 2008;51:5663-79
22. Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, et al. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol 2013; 71:1315-23
23. Okabe S, Tauchi T, Tanaka Y, Kitahara T, Kimura S, Maekawa T, et al. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. Cancer Biol Ther 2014;15:207-15
24. Ezell SA, Mayo M, Bihani T, Tepsuporn S, Wang S, Passino M, et al. Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B-cell lymphoma. Oncotarget 2014;5:4990-5001
25. Zhong H, Fazenbaker C, Breen S, Chen C, Huang J, Morehouse C, et al. MEDI-573, alone or in combination with mammalian target of rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas. Mol Cancer Therapeutic 2014;13:2662-73
26. Holt SV, Logie A, Davies BR, Alferez D, Runswick S, Fenton S, et al. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). Cancer Res 2012;72:1804-13
27. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93
28. Nogova L, Sequist LV, Cassier PA, Hidalgo M, Delord J-P, Schuler MH, et al. Targeting FGFR1-Amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398. Journal of clinical oncology 2014;32: abstr 8034
29. Paik PK, Shen R, Ferry D, Soria J-C, Mathewson A, Kilgour E, et al. A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: preliminary antitumor activity and pharmacodynamic data. J Clin Oncol 2014;32:abstr 8035.